NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSN) will likely be releasing its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect NeuroSense Therapeutics to post earnings of ($0.1050) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, April 6, 2026 at 4:00 PM ET.

NeuroSense Therapeutics Stock Performance

NRSN stock opened at $0.74 on Tuesday. The company’s 50-day simple moving average is $0.91 and its 200 day simple moving average is $1.01. NeuroSense Therapeutics has a 52 week low of $0.68 and a 52 week high of $2.60.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Finally, Roth Mkm started coverage on NeuroSense Therapeutics in a research report on Tuesday, March 10th. They set a “buy” rating and a $3.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, NeuroSense Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the second quarter worth $54,000. Squarepoint Ops LLC increased its holdings in NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the period. Finally, Two Sigma Investments LP bought a new position in NeuroSense Therapeutics during the 3rd quarter worth $26,000. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.